- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Mepolizumab – March 2016
Mepolizumab: 100 mg/10 mL vial, powder for injection, 1, Nucala®
Last updated
15 July 2016